Lumeris
Lumeris is a healthcare transformation company offering Primary Care as a Service powered by its flagship AI platform, Tom™.
Secondary Market Price
How Lumeris Measures Up
To help you manage your Lumeris equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Lumeris's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Lumeris Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Lumeris's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Lumeris is a healthcare transformation company that provides technology and services to health systems and provider organizations. The company's core offering is its "Primary Care as a Service" (PCaaS) model, which is powered by an AI platform named Tom™. This platform uses predictive analytics and automation to help physicians and care teams with administrative tasks and care orchestration. Lumeris currently supports organizations that manage a combined $9.3 billion in medical expenses for 1.4 million patients. Physician-founded in 2012, the company is headquartered in Maryland Heights, Missouri, and leverages over 15 years of experience in managing Medicare risk through its affiliate, Essence Healthcare.
The company is focused on expanding its AI-powered solutions and strategic partnerships. In May 2024, Lumeris announced a $100 million Series A funding round with investors that included Deerfield Management and Endeavor Health. Lumeris is collaborating with AVIA to launch a program to accelerate innovation in health systems and is working with Google Cloud to enhance its Tom™ platform. Ochsner Health is also deploying the Tom™ platform for its primary care operations. In early 2024, the company was named a Leader in the IDC MarketScape for U.S. Value-Based Care Strategic Consulting Services 2025–2026.
- Deerfield Management
- Endeavor Health
- Kleiner Perkins
- Sandbox Industries
- BlueCross BlueShield Venture Partners
- JDLinx
- Northwood Investors LLC
- Nimble Partners
- New York Life Investments
- Camden Partners
- Passport Capital
- Cerner
- Co-Founder, W. Michael Long
- Co-Founder, Nigel Ohrenstein
- Co-Founder, Richard Jones
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Lumeris worth joining?
Deciding whether to join a company like Lumeris involves evaluating many factors, including the potential value of its equity compensation. Tools like Prospect can help you model the future value of your equity and understand its potential impact on your finances.
What should I do with my Lumeris stock?
Managing private company stock involves complex decisions about when to exercise options and how to plan for taxes. Platforms like Prospect offer personalized strategies and tax optimization tools to help you make the most of your equity.
Can you sell Lumeris stock?
Selling stock in a private company like Lumeris is typically possible during specific liquidity events, such as a tender offer or on a secondary market. Prospect's tools can help you navigate these opportunities and determine the most tax-optimal shares to sell.
How can I find the value of my Lumeris stock?
The value of private stock is determined by 409A valuations, but these don't always reflect the company's future potential. To get a better forecast, you can use platforms like Prospect, which use proprietary models to project your equity's future value.
What is Lumeris's equity worth?
As a private company, Lumeris's exact equity valuation is not public information and can change with new funding rounds and performance. You can use predictive modeling tools from services like Prospect to help forecast the potential worth of your specific holdings.
What is Lumeris's stock ticker symbol?
Lumeris is a private company, so it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are assigned only when a company undergoes an initial public offering (IPO).
Can I buy or sell Lumeris stock?
As a private company, buying Lumeris stock is generally restricted to accredited investors during specific funding rounds, while selling is typically limited to company-approved liquidity events like tender offers. If you are an employee with equity, platforms like Prospect can help you plan for selling opportunities.
What is the criteria to buy or invest in Lumeris stock?
Investing in a private company like Lumeris is typically reserved for venture capital firms and accredited investors who meet specific income or net worth requirements defined by financial regulators. Employees may also receive equity as part of their compensation package.
